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Background: Type 1 diabetes is associated with more severe glycemic variability and more frequent hypoglycemia than type 2 
diabetes. Glycemic variability is associated with poor glycemic control and diabetic complications. In this study, we demonstrate 
the clinical usefulness of serum 1,5-anhydroglucitol (1,5-AG) for assessing changes in glycemic excursion in type 1 diabetes.
Methods: Seventeen patients with type 1 diabetes were enrolled in this study. A continuous glucose monitoring system (CGMS) 
was applied twice at a 2-week interval to evaluate changes in glycemic variability. The changes in serum glycemic assays, includ-
ing 1,5-AG, glycated albumin and hemoglobin A1c (HbA1c), were also evaluated.
Results: Most subjects showed severe glycemic excursions, including hypoglycemia and hyperglycemia. The change in 1,5-AG 
level was significantly correlated with changes in the glycemic excursion indices of the standard deviation (SD), mean amplitude 
of glucose excursion (MAGE), lability index, mean postmeal maximum glucose, and area under the curve for glucose above 180 
mg/dL (r=–0.576, –0.613, –0.600, –0.630, and –0.500, respectively; all P<0.05). Changes in glycated albumin were correlated 
with changes in SD and MAGE (r=0.495 and 0.517, respectively; all P<0.05). However, changes in HbA1c were not correlated 
with any changes in the CGMS variables.
Conclusion: 1,5-AG may be a useful marker for the assessment of short-term changes in glycemic variability. Furthermore, 1,5-
AG may have clinical implications for the evaluation and treatment of glycemic excursions in type 1 diabetes.
Keywords: 1,5-anhydroglucitol; Continuous glucose monitoring; Type 1 diabetes; Glycemic variability
Corresponding author: Bong Soo Cha
Division of Endocrinology and Metabolism, Department of Internal Medicine, 
Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 
120-752, Korea
E-mail: bscha@yuhs.ac 
Received: Apr. 21, 2014; Accepted: Nov. 21, 2014
INTRODUCTION
Chronic hyperglycemia is a well-established risk factor for mi-
crovascular and macrovascular complications in diabetes 
[1,2]. Recent studies have reported that glycemic excursions, 
including both hypoglycemia and hyperglycemia, are inde-
pendent risk factors for macrovascular complications [3-5]. 
 Hypoglycemia occurs more frequently in type 1 diabetes 
than in type 2 diabetes [6]. The titration of insulin doses is in-
dispensable for glycemic control of type 1 diabetes. However, 
efforts to obtain ideal glycemic control often accompany hy-
poglycemia, and fear of hypoglycemia often makes glycemic 
control difficult [7,8]. Therefore, glycemic excursion, includ-
ing hypoglycemia and hyperglycemia, should be evaluated 
and corrected for proper treatment of type 1 diabetes [9].
 A continuous glucose monitoring system (CGMS) is cur-
rently used to evaluate glycemic excursion, and this is espe-
cially useful for type 1 diabetes [10]. Unfortunately, CGMS is 
expensive and inconvenient because patients must be attached 
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in clinical practice. The serum marker hemoglobin A1c 
(HbA1c) is the gold standard for the evaluation of overall glyce-
mic control. However, previous studies have shown that 
HbA1c levels do not accurately represent glucose fluctuations 
[5,11]. Therefore, surrogate serum markers that reflect glyce-
mic excursions are needed.
 1,5-anhydroglucitol (1,5-AG) is naturally occurring in the 
human body and is structurally similar to glucose [12]. It is fil-
tered in the kidneys and 99.9% is reabsorbed in the renal tu-
bules. Under normal conditions, serum levels of 1,5-AG are 
constant due to a balance between intake and excretion in renal 
tubules. When blood glucose is higher than the renal threshold 
of approximately 180 mg/dL, glucose inhibits renal re-absorp-
tion of 1,5-AG and serum 1,5-AG levels [13]. Thus, serum 1,5-
AG levels are inversely correlated with hyperglycemia. Interest-
ingly, recent studies have reported that 1,5-AG could reflect 
glucose excursion over a short term period ranging from 1 to 3 
days to several weeks [14-16]. However, no previous studies 
have evaluated whether changes in serum 1,5-AG levels are 
correlated with changes in glycemic excursions.
 The aim of this study was to evaluate whether 1,5-AG is a 
useful marker for evaluating short term changes in glycemic 
excursion. In this study, we examined whether 1,5-AG could 
be a useful serum assay for assessment and treatment of glyce-
mic excursion in type 1 diabetes.
METHODS
Study design and patients
Seventeen subjects aged 18 to 65 years with type 1 diabetes 
were recruited at Severance Hospital, Seoul, Korea. All sub-
jects were treated with multiple daily injections (MDIs) or 
continuous subcutaneous insulin infusion (CSII). The exclu-
sion criteria for this study included severe medical illnesses, 
pregnancy, anemia, serum creatinine >1.5 mg/dL, or serum 
albumin <3.5 mg/dL. CGMS was applied to each patient twice 
with a 2-week interval. The serum glycemic markers were si-
multaneously measured for the 2-week interval. 
 After the first CGMS analysis, the results from CGMS data 
were analyzed by a single clinician. The patients were subse-
quently presented with their results and were taught how to 
manage glucose control via exercise, diet, and adjustment of 
insulin dosage. The study protocol was approved by the Insti-
tutional Review Board of Severance Hospital (4-2011-0144). 
Written informed consent was obtained from all participants. 
Continuous glucose monitoring system and data analysis 
A CGMS (Medtronic Minimed, Northridge, CA, USA) was ap-
plied to each subject for approximately 72 hours at a 2-week in-
terval. The CGMS sensor measured interstitial tissue fluid glu-
cose every 5 minutes. For calibration, patients were instructed 
to check their seven-point fingerstick glucose profiles before a 
meal, 2 hours after a meal, and at bedtime and to enter the data 
into the CGMS. After 72 hours, the recorded data were down-
loaded using Medtronic CGMS software. The data recorded 
during the middle 48 hours were used for analysis in this study. 
To evaluate glycemic variability, the standard deviation (SD), 
continuous overall net glycemic action (CONGA), mean am-
plitude of glycemic excursion (MAGE), lability index (LI), and 
mean post-meal maximum glucose (MPMG) were calculated 
using the CGMS data. CONGA-1 was calculated as the SD of 
the differences between glucose level and the corresponding 
glucose level measured 1 hour earlier [17]. MAGE was defined 
as the mean of the absolute difference in peak-to nadir or na-
dir-to peak direction and was used for assessing intra-day gly-
cemic variability [18]. More than one SD of glycemic excur-
sions were taken into account for MAGE analysis. The LI is cal-
culated by dividing the sum of the square of the difference be-
tween successive glucose measurements by the difference in 
time between measurements [19]. MPMG is the mean of maxi-
mal blood glucose levels at 4 hours after consumption of each 
meal [20]. The area under the curve for a glucose level greater 
than 180 mg/dL (AUC-180) was measured as the total area of 
glucose excursions greater than 180 mg/dL [21]. 
Measurement of serum glycemic markers
Serum levels of fasting glucose and postprandial glucose were 
measured by standard methods. Serum 1,5-AG was measured 
using an enzymatic assay kit (Kyowa Medex, Tokyo, Japan) and 
an auto-Hitachi 7600 DDP analyzer (Hitachi High-Technolo-
gies Co., Tokyo, Japan) according to the manufacturers’ in-
structions. Serum glycated albumin was measured enzymati-
cally using an albumin-specific proteinase (ketoamine oxidase) 
and albumin assay reagent (LUCICA GA-L; Asahi Kasei Phar-
ma Co., Tokyo, Japan) with a Hitachi 7699 P-module auto-ana-
lyzer (Hitachi Instruments Service, Tokyo, Japan). HbA1c was 
measured by high-performance liquid chromatography using 
Variant TM II Turbo (Bio-Rad Laboratories, Hercules, CA, 
USA). The normal ranges are 10.7 to 32.0 μg/mL for 1,5-AG, 
11% to 16% for glycated albumin, and 4.0% to 6.0% for HbA1c.
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Statistical analysis
The data are expressed as the mean with SD or number (pro-
portions). The data changes were established by calculating 
the differences between the data for a 2-week interval in each 
subject. Changes of glycemic markers and CGMS variables for 
a 2-week interval were compared using a nonparametric Wil-
coxon rank-sum test. The correlation coefficients were deter-
mined using Spearman correlation coefficients. Correlations 
between changes in glycemic variability indices and changes 
in serum glycemic markers were analyzed according to base-
line mean glucose level (<180 and ≥180 mg/dL). A log trans-
formation was performed for skewed data before further anal-
yses. All statistical analyses were conducted in SPSS version 
18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
The baseline characteristics of the subjects are shown in Table 1. 
The mean age of the subjects was 49 years, and the mean dura-
tion of diabetes was 11.2 years. All subjects were treated with 
either MDI (88%) or CSII (12%). We collected data at baseline 
and 2 weeks later. The levels of mean 1,5-AG and mean glycat-
ed albumin improved (P=0.017 and P=0.004, respectively). 
However, there were no differences in mean HbA1c (P=0.077). 
There were no significant differences between the baseline and 
CGMS measures after 2 weeks. 
Correlations between changes in serum glycemic assays 
and changes in CGMS measures
We then compared the relationship between changes in serum 
Table 1. Patient characteristics
Variable Baseline 2 Weeks later P value
Age, yr 49±10 (32–65)
Gender, male/female 8/9
Duration of diabetes, yr 11.2±6.6 (2–24)
BMI, kg/m2 22.6±3.8 (17.6–28.4)
Serum creatinine, mg/dL 0.97±0.20 (0.70–1.22)
Treatment
    MDI 15 (88)
    CSII 2 (12)
Glycemic assays
    1,5-AG, μg/mL 3.4±2.7 (0.7–10.3) 4.2±3.1 (1.3–11.7) 0.017
    Glycated albumin, % 26.6±5.0 (18.4–35.0) 24.5±3.5 (18.4–30.0) 0.004
    HbA1c, % 8.8±1.4 (6.4–10.9) 8.6±1.2 (6.8–10.6) 0.077
CGMS measures
    Mean blood glucose, mg/dL 164±34 (115–247) 168±35 (123–260) 0.551
    SD, mg/dL 58±13 (37–79) 67±17 (46–96) 0.826
    CONGA-1, mg/dL 146±34 (95–232) 152±34 (108–235) 0.826
    MAGE, mg/dL 126±34 (67–169) 142±43 (64–230) 0.152
    LI, mg/dL 96±54 (40–244) 105±46 (49–207) 0.875
    MPMG, mg/dL 233±43 (152–315) 248±58 (171–353) 0.683
    AUC-180, mg∙dL–1∙day–1 20.3±17.0 (1.4–71.2) 25.7±21.2 (3.7–84.9) 0.900
Values are presented as mean±standard deviation (range) or number (%).
BMI, body mass index; MDI, multiple daily injection; CSII, continuous subcutaneous insulin infusion; 1,5-AG, 1,5-anhydroglucitol; HbA1c, 
hemoglobin A1c; CGMS, continuous glucose monitoring system; SD, standard deviation; CONGA-1, continuous overlapping net glycemic ac-
tion with 1 hour time intervals; MAGE, mean amplitude of glucose excursion; LI, lability index; MPMG, mean post-meal maximum glucose; 
AUC-180, area under the curve for glucose above 180 mg/dL.
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glycemic assays and changes in CGMS variability indices for a 
2-week interval (Table 2). The results showed the change in 
1,5-AG (∆1,5-AG) level was significantly correlated with 
changes in most of the variability indices of CGMS. The ∆1,5-
AG was correlated with changes in SD (r=–0.576, P=0.016), 
MAGE (r=–0.613, P=0.009), LI (r=–0.600, P=0.011), and 
MPMG (r=–0.630, P=0.007). A change in glycated albumin 
(∆glycated albumin) was correlated with changes in a several 
variability indices, including changes in SD (r=0.495, P=0.043) 
and MAGE (r=0.517, P=0.033). However, changes in HbA1c 
(∆HbA1c) did not show a significant correlation with changes 
in any CGMS variability indices.
Correlations between changes in serum glycemic assays 
and changes in CGMS measures according to glycemic 
control 
To further investigate the clinical usefulness of these findings, 
the subjects were classified into either the moderate glycemic 
control group (baseline mean CGMS glucose <180 mg/dL) or 
the poor glycemic control group (baseline mean CGMS glu-
cose ≥180 mg/dL) (Table 3). In subjects with moderate control 
(n=11), the ∆1,5-AG showed a significant correlation with 
changes in CGMS variability indices (mean blood glucose, SD, 
CONGA-1, MPMG, and AUC-180 [r=–0.609, r=–0.645, r= 
–0.755, r=–0.764, and r=–0.727, respectively; all P<0.05]). 
∆Glycated albumin was only correlated with changes in 
MAGE (r=0.662, P=0.026). Additionally, ∆HbA1c showed no 
significant correlation with changes in any CGMS variability 
indices. Interestingly, in the poor glycemic control group 
(n=6), ∆1,5-AG, ∆glycated albumin, and ∆HbA1c showed no 
correlations with changes in CGMS glycemic variability indi-
ces.
DISCUSSION
The Diabetes Control and Complication Trial and the United 
Kingdom Prospective Diabetes Study demonstrated that 
chronic hyperglycemia is a risk factor for diabetic complica-
tions. Thus, improving glycemic control can reduce diabetic 
complications [22,23]. Lowering hyperglycemia is currently 
the main treatment of diabetic patients. However, many recent 
reports have demonstrated that glycemic variability is associ-
ated with diabetic complications independent from hypergly-
cemia [24,25]. The reason for this finding could be that glyce-
mic variability increases oxidative stress or inflammation, 
which are both important mediators of hyperglycemia-medi-
ated cellular damage [26,27]. HbA1c is a proper marker for 
the evaluation of chronic hyperglycemia and is most widely 
used for determining overall glycemic control in clinical prac-
tice. However, it has been reported that HbA1c is not suitable 
for the evaluation of short-term glycemic control or assess-
ment of glucose fluctuation [23]. In type 1 diabetes, glycemic 
variability is usually severe and is important. In relatively well-
controlled type 1 diabetes, severe glycemic variability and hy-
Table 2. Correlations between changes of the continuous glucose monitoring system measures and glycemic assays
Variable
∆HbA1ca ΔGlycated albumina Δ1,5-AGa
r P value r P value r P value
ΔGlycated albumina 0.594 0.012 - - - -
Δ1,5-AGa –0.539 0.026 –0.683 0.003 - -
ΔMean blood glucose –0.124 0.636 0.211 0.416 –0.324 0.205
ΔSD 0.232 0.370 0.495 0.043 –0.576 0.016
ΔCONGA-1 0.113 0.235 0.296 0.249 –0.412 0.101
ΔMAGE 0.221 0.394 0.517 0.033 –0.613 0.009
ΔLI 0.315 0.218 0.373 0.141 –0.600 0.011
ΔMPMG 0.069 0.793 0.362 0.444 –0.630 0.007
ΔAUC-180 0.038 0.885 0.378 0.443 –0.500 0.041
Δ The differences of the variables for the 2-week interval.
HbA1c, hemoglobin A1c; 1,5-AG, 1,5-anhydroglucitol; SD, standard deviation; CONGA-1, continuous overlapping net glycemic action with 1 
hour time intervals; MAGE, mean amplitude of glucose excursion; LI, lability index; MPMG, mean post-meal maximum glucose; AUC-180, 
area under the curve for glucose above 180 mg/dL. 
aLog transformed.
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poglycemia often occur and are important causes of low treat-
ment compliance [7,28]. Thus, proper assessment of glycemic 
variability and hypoglycemia is very important for treatment 
of type 1 diabetes. In our study, patients with type 1 diabetes 
showed severe glycemic variability. More than half of the sub-
jects showed both severe hypoglycemia (<70 mg/dL) and hy-
perglycemia (>400 mg/dL) when analyzed with CGMS (data 
not shown). In this study, 1,5-AG levels in subjects were very 
low (3.8±2.8 μg/mL) when considering the normal range of 
1,5-AG is 10.7 to 32.0 μg/mL. This finding might be suggestive 
of severe glycemic variability in type 1 diabetes. The mean 
MPMG (240±39 mg/dL) and mean AUC-180 (23.0±14.6 
mg∙dL–1∙day–1) indicated there was severe postprandial hyper-
glycemic excursion despite a relatively favorable overall glyce-
mic control of the mean glucose level (166±28 mg/dL). The 
high mean SD values (63±12 mg/dL) also suggested that there 
was demonstrable glycemic excursion, including both hypo-
glycemia and hyperglycemia. 
 CGMS is the main method currently used for the evalua-
tion of glycemic variability. Many reports have noted that 
CGMS could be useful to evaluate the glycemic status and im-
proved glycemic control in type 1 diabetes [11]. Unfortunately, 
CGMS is not often used in clinical practice because it is ex-
pensive and inconvenient. Therefore, there is a need for a sim-
ple and convenient method of glycemic variability assessment.
 When using serum glycemic assays to evaluate the im-
provement or deterioration of glycemic excursion or assess-
ment of a treatment effect on glycemic excursion, the changes 
in these markers should be associated with changes in glyce-
mic variability. There are no prior studies establishing that 
Table 3. Correlations between the changes of the continuous glucose monitoring system measures and glycemic assays accord-
ing to the basal mean glucose level (<180 and ≥180 mg/dL)
Variable
∆HbA1ca ΔGlycated albumina Δ1,5-AGa
r P value r P value r P value
Moderate control (n=11)
   ΔGlycated albumina 0.816 0.002 - - - -
   Δ1,5-AGa 0.459 0.156 –0.589 0.057 - -
   ΔMean blood glucose 0.248 0.463 0.187 0.581 –0.609 0.047
   ΔSD 0.578 0.063 0.603 0.050 –0.645 0.032
   ΔCONGA-1 0.330 0.321 0.370 0.263 –0.755 0.007
   ΔMAGE 0.495 0.121 0.662 0.026 –0.555 0.077
   ΔLI 0.395 0.230 0.420 0.198 –0.555 0.077
   ΔMPMG 0.468 0.147 0.493 0.123 –0.764 0.006
   ΔAUC-180 0.440 0.175 0.553 0.078 –0.727 0.001
Poor control (n=6)
   ΔGlycated albumina –0.029 0.956 - - - -
   Δ1,5-AGa –0.618 0.191 0.143 0.787 - -
   ΔMean blood glucose –0.647 0.165 0.714 0.111 0.314 0.544
   ΔSD –0.235 0.653 0.143 0.787 0.543 0.266
   ΔCONGA-1 –0.794 0.059 0.486 0.329 0.257 0.623
   ΔMAGE –0.206 0.695 0.200 0.704 0.257 0.623
   ΔLI 0.500 0.312 0.371 0.468 –0.371 0.468
   ΔMPMG 0.059 0.912 0.371 0.468 –0.543 0.266
   ΔAUC-180 –0.500 0.312 0.771 0.072 0.257 0.623
Δ The differences of the variables for the 2-week interval.
HbA1c, hemoglobin A1c; 1,5-AG, 1,5-anhydroglucitol; SD, standard deviation; CONGA-1, continuous overlapping net glycemic action with 1 
hour time intervals; MAGE, mean amplitude of glucose excursion; LI, lability index; MPMG, mean post-meal maximum glucose; AUC-180, 
area under the curve for glucose above 180 mg/dL. 
aLog transformed.
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changes of serum glycemic assays reflect short term changes 
in glucose variability. 
 In this study, changes in the 1,5-AG level were significantly 
correlated with changes in CGMS variability indexes, such as 
SD, MAGE, LI, MPMG, and AUC-180. The changes in glycat-
ed albumin showed a partial correlation with changes in the 
CGMS variability indexes (SD and MAGE). As expected from 
previous studies, changes in HbA1c did not show a correlation 
with changes of any variability indexes. There were no gender 
differences correlated between changes of serum glycemic 
markers and changes of CGMS variability markers (data not 
shown). Interestingly, changes in 1,5-AG reflected changes in 
glycemic variability, especially in patients with a relatively 
lower mean blood glucose level, but not in cases with higher 
mean blood glucose levels. This finding is consistent with pre-
vious clinical studies showing that 1,5-AG is more useful in 
evaluating glycemic variability in well- or moderately con-
trolled patients [14,15,20]. The reason for this finding is not 
yet clear. However, the characteristics of 1,5-AG might provide 
a possible explanation. In poorly controlled subjects, 1,5-AG 
levels decrease substantially (nearly an exhausted state). It 
might take time until the 1,5-AG level is restored. Therefore, 
changes in the 1,5-AG level could be less apparent in poorly 
controlled subjects than in well-controlled subjects. This find-
ing might explain the differing results between the well-con-
trolled and poorly controlled subjects in this study. Consistent 
with our study, Dungan [14] proposed that the 1,5-AG level is 
appropriate for the evaluation of glycemic variability in well- 
or moderately controlled patients, which could be appropriate 
for monitoring short term overall hyperglycemia in poorly 
controlled patients. Therefore, 1,5-AG could be a useful mark-
er in subjects with severe glycemic excursions despite fair gly-
cemic control. 
 This is the first study to demonstrate that 1,5-AG level 
changes reflect short term changes in glycemic variability. The 
limitation of this study is the small number of enrolled sub-
jects. Further studies are required to determine which subjects 
might benefit the most from assessment of 1,5-AG. It is known 
that the 1,5-AG level could be different in patients with renal 
impairment, severe liver dysfunction, pregnancy, or persistent 
glucosuria. Additional studies evaluating the usefulness of 1,5-
AG in these patients are needed.  
 In conclusion, serum 1,5-AG might be a useful marker for 
assessing short-term changes in glucose variability in Korean 
type 1 diabetes, especially in moderately controlled subjects. 
Furthermore, 1,5-AG levels may be valuable in assessing 
changes in glycemic variability and could be helpful in achiev-
ing better glycemic control with less glycemic excursions. 
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